-+ 0.00%
-+ 0.00%
-+ 0.00%

Akebia Therapeutics Established Its Rare Kidney Disease Pipeline Comprising Two Core Product Candidates- ADX-097 (Now Referred To As AKB-097) And Praliciguat, Both Trials Planned To Start Treating Subjects In 2026

Benzinga·12/01/2025 12:08:43
Listen to the news

Akebia acquired all rights to AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor, from Q32 Bio Inc. (NASDAQ:QTTB) and believes AKB-097 has applicability across a wide range of complement-mediated rare kidney diseases. 

On November 28, 2025, Akebia and Q32 Bio signed an Asset Purchase Agreement (APA) under which Akebia acquired global rights to Q32 Bio's ADX-097 (now referred to as AKB-097). In consideration, Akebia paid Q32 Bio an upfront payment of $7.0 million. Akebia will also make a $3.0 million payment upon the six-month anniversary of the closing, as well as additional development and regulatory milestones, commercial milestones and tiered royalties on annual net sales of AKB-097.